Snowball logo
logo
4248

ImmuneOncia

424870 • KQ
₩2,850.00₩0.00  (0%)
Estimate
Beta
-0.189
Growth
Net income, YoY
-24.27%
FCF, YoY
-0.44%
About the company
Ticker
424870
ISIN
Country
South Korea
Sector (GICS)
Other
ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer. The company also develops non clinical products, which includes IMC-201, a CD47xPD-L1 dual antibody based immunotherapy; and IMC-202, a PD-L1xTIGIT dual antibody based immunotherapy. The company was incorporated in 2016 and is headquartered in Yongin-si, South Korea. ImmuneOncia Therapeutics, Inc. operates as a subsidiary of Yuhan Corporation.

Frequently asked questions

What sector does ImmuneOncia (424870) operate in?

ImmuneOncia belongs to the Other sector and operates in the Biotechnology industry.

What is ImmuneOncia (424870) current stock price?

As of the latest data, ImmuneOncia stock price is ₩2,850, with a previous close of ₩2,850.

What is ImmuneOncia (424870) current market capitalization?

ImmuneOncia market cap is approximately 260.13 billion.

What is ImmuneOncia (424870) EBITDA?

ImmuneOncia EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.72 billion.

Does ImmuneOncia (424870) pay dividends?

No. ImmuneOncia does not pay a dividend.

What is ImmuneOncia (424870) beta (volatility) score?

ImmuneOncia has a beta of -0.189, indicating lower volatility than the overall market.